by Dr Aleksandra Havelka Assays for NT-proBNP form a key part of diagnosing/ruling out, predicting and managing heart failure. CLI chatted to Dr Aleksandra Havelka (Gentian Diagnostics) to find out more about the challenges and limitations of measuring NT-proBNP concentrations, particularly the effects of glycosylation, and what developments are on the horizon to overcome these […]
by Dr Osaretin Emmanuel Asowata The detection of Pneumocystis jirovecii in immunocompromised patients is crucial for the treatment of Pneumocystis jirovecii pneumonia (PCP) and to prevent invasive infection. However, PCP can be challenging to diagnose clinically, as symptoms are non-specific. There are several laboratory methods that can be used to diagnose PCP and their advantages […]
University of Bern makes landmark move to AWS-powered HALO AP platform for diagnostic tissue analysis
Laboratories are among the most resource-intensive environments in scientific research, consuming vast quantities of energy, water, and disposable materials. However, a growing movement towards sustainable laboratory practices is gaining momentum within the bioanalytical sector, as evidenced by Synexa Life Sciences’ recent achievement.
Cambridge-based JuliaHub is strengthening its position in the pharmaceutical sector with significant investment in its CFR Part 11-compliant platform, offering integrated solutions for pharmacometrics, modelling and regulatory compliance.
The biotechnology sector marks a significant advancement in genetic medicine with EG 427’s achievement in treating neurogenic bladder using a novel herpes-based vector approach.
In a significant development for radiopharmaceutical advancement, isotope technology provider Eckert & Ziegler has established a comprehensive partnership with Bicycle Therapeutics to supply radioisotopes and manufacture novel bicyclic peptide-based radiopharmaceuticals for upcoming clinical trials.
Seth Benson joins the executive team at Nuclera as Chief Financial Officer, bringing extensive life sciences financial expertise to drive the company’s global commercial expansion of its eProtein Discovery system following a $75 million financing round
Celonic Group, a dedicated biologics contract development and manufacturing organisation (CDMO), has finalised a multi-year commercial manufacturing agreement with LINDIS Biotech for catumaxomab production. The announcement, made on 19 February 2025, establishes Celonic’s Heidelberg facility as the manufacturing hub for this first-in-class therapeutic antibody.
Sphere Fluidics, a pioneer in droplet-based microfluidics technology, has announced its comprehensive rebranding to Sphere Bio. The name change, revealed on 25th February 2025, signifies the company’s strategic pivot and commercial growth trajectory as it continues to expand its footprint in the single-cell analysis market.
May 2026
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.